Prizma

G Medical Innovations’ CEO Issues Update to Shareholders, August 2023

Retrieved on: 
Monday, August 7, 2023
Blood pressure, HTK, Dr. G: Medical Examiner, Workforce, Software as a service, Limitless, Marketing, EVP, Sleep, Sleep apnea, RHM, AdventHealth, HTK Ltd, CLIA, Healthcare Facilities Accreditation Program, Hospital, MHealth, Patient, Physician, Sleep disorder, Algorithm, Corporation, Memorial Hermann Health System, Vertically transmitted infection, Amazon Marketplace, Growth, R, CFO, Conditional sentence, Software, Management, Food delivery, Pharmaceutical industry, Central Florida, Amazon, Prizma

Rehovot, Israel, Aug. 07, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (“G Medical Innovations” or the “Company”), a global leader in next-generation mobile health (mHealth) and digital health, today issued the following update to shareholders from President and CEO Dr. Yacov Geva.

Key Points: 
  • Rehovot, Israel, Aug. 07, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (“G Medical Innovations” or the “Company”), a global leader in next-generation mobile health (mHealth) and digital health, today issued the following update to shareholders from President and CEO Dr. Yacov Geva.
  • We are proud to report that at this halfway point of 2023, G Medical has met several significant milestones and is on track to show revenue growth and gain profitability.
  • We plan to launch this service during the 4th quarter of 2023 and we are already in discussions with hospitals.
  • Our management team is razor focused on increasing revenue during 2023 and we are looking forward to an even brighter 2024 and beyond.

Dover Fueling Solutions Introduces DX Power to Integrate EV Chargers with Prizma, the Company's Connected Mobility and Convenience Hub

Retrieved on: 
Wednesday, March 15, 2023
Product management, Sale, Senior, POS, ChargePoint, NYSE, EV, DX, Investment, DOV, OCPP, DFS, Online shopping, Prizma

DX Power is a solution that integrates electric vehicle (EV) chargers with Prizma, DFS's connected mobility and convenience hub, to provide retailers with improved visibility and control, and customers with flexible payment options.

Key Points: 
  • DX Power is a solution that integrates electric vehicle (EV) chargers with Prizma, DFS's connected mobility and convenience hub, to provide retailers with improved visibility and control, and customers with flexible payment options.
  • As a modular and open cloud-based platform, DX Power can interface with any EV charger and ChargePoint Operator to provide a frictionless customer journey.
  • "DX Power is a solution that can set a fuel retail business apart from the competition," said Raf Tormans, Senior Manager, Product Management, DFS.
  • DX Power leverages the Prizma ecosystem and existing loyalty programs on fuel retail sites to ensure EV chargers are included in transactions through the POS system.

G Medical Innovations to announce receiving of 2 (two) granted patents from the USPTO for its Prizma care and other physiological sensors developed by the company.

Retrieved on: 
Monday, December 5, 2022
Degenerative disease, Cardiovascular disease, Temperature, Light, Reading, Patent, Algorithm, Pressure, Diabetes, CVD, Telehealth, Short QT syndrome, Dr. G: Medical Examiner, Software patents under United States patent law, Smartphone, Vital signs, MHealth, Patient, Medical device, Prizma

This patent integrates sensing mechanism that allows the monitoring system to analyze the sensing condition (pressure, ambient temperature, light, conductivity, etc.)

Key Points: 
  • This patent integrates sensing mechanism that allows the monitoring system to analyze the sensing condition (pressure, ambient temperature, light, conductivity, etc.)
  • This allows higher and more accurate sensing that results in reducing false positive reading including false alarms.
  • This will allow the company to increase the attractiveness of its products, boost its market activity and achieve a bigger market share.
  • G Medical Innovations Holdings Ltd. is a healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms.

G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) Announces Receipt of Notice of Deficiency with Nasdaq Continued Listing Requirements

Retrieved on: 
Tuesday, November 22, 2022
COVID-19, Degenerative disease, COVID-19 testing, ECG, Laboratory, CVD, Antibody, Notice, Patient, Cardiovascular disease, Vital signs, Telehealth, Diabetes, Security (finance), Letter, MHealth, Calendar, Risk, Smartphone, Severe acute respiratory syndrome coronavirus 2, Rope, Prizma

In accordance with Nasdaq Rule 5810(c)(2)(A), the Company has 45 calendar days, or until January 6, 2023, to submit a plan to regain compliance.

Key Points: 
  • In accordance with Nasdaq Rule 5810(c)(2)(A), the Company has 45 calendar days, or until January 6, 2023, to submit a plan to regain compliance.
  • The Company intends to evaluate its courses of action and to timely submit a plan to Nasdaq to regain compliance with the Nasdaq minimum shareholders equity requirement.
  • About G Medical Innovations Holdings Ltd.
    G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms.
  • G Medical Innovations Holdings Ltd.

G Medical Innovations Announces First Half 2022 Financial Results and Provides Business Update

Retrieved on: 
Friday, November 18, 2022
COVID-19, Growth, Degenerative disease, Short QT syndrome, Patient, Cardiovascular disease, Government, Electrocardiography, Vital signs, Annual report, Telehealth, Research, Diabetes, PCR, Security (finance), Prizma, Special-purpose acquisition company, MHealth, Risk, Smartphone, Collection, Dr. G: Medical Examiner, Animal, Life insurance, Medical device, Rope

Irvine, CA, Nov. 18, 2022 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (G Medical or the Company), an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms, today announced its financial results and provided a business update for the six months ended June 30, 2022.

Key Points: 
  • Irvine, CA, Nov. 18, 2022 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (G Medical or the Company), an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms, today announced its financial results and provided a business update for the six months ended June 30, 2022.
  • Cash and cash equivalents as of June 30, 2022, were $1,509 thousand, compared to $6,034 thousand as of December 31, 2021.
  • About G Medical Innovations Holdings Ltd.
    G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms.
  • The Companys actual results and financial condition may differ materially from those indicated in the forward-looking statements.

G Medical Innovations is introducing a Monkeypox consumer home health test kit, along with 30 new direct to consumer home health testing kits with 24 to 48 hours results

Retrieved on: 
Thursday, October 6, 2022
MHealth, Short QT syndrome, CLIA, Cardiovascular disease, Pharmacy, Smartphone, Patient, Privacy, Dr. G: Medical Examiner, Private Securities Litigation Reform Act, Degenerative disease, Company, Saliva, CEO, CVD, Diabetes, Telehealth, Vital signs, Solution, Algorithm, Medical device, Prizma

IRVINE, California, Oct. 06, 2022 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) (the “Company” or “G Medical Innovations”) today announced that its wholly owned subsidiary, G. Medical Health and Wellness, Inc., has developed 31 different at-home health tests kits that are expected to be available to consumers during Q4-2022 through online and later popular big-box retail sites and pharmacies across the United States.

Key Points: 
  • Consumers should expect to pay anywhere from$50to$260depending on the tests complexity.
  • As telehealth and telemedicine industry pioneers, the management ofG Medical Innovationshas been offering patient home care monitoring and service for over 30 years.
  • G Medical Innovations Holdings Ltd.is a healthcare company engaged in the development of next-generation mHealth and telemedicine solutions and monitoring service platforms.
  • References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release.

G Medical Innovations is introducing affordable, new direct to consumer home health testing kits with quick results

Retrieved on: 
Wednesday, July 13, 2022
Online, Telehealth, Security (finance), U.S. Securities and Exchange Commission, Pharmacy, Dr. G: Medical Examiner, Privacy, Solution, Diabetes, Food, Vital signs, Company, Wellness, CLIA, Patient, CEO, Algorithm, GLOBE, Cardiovascular disease, MHealth, Private Securities Litigation Reform Act, Glycated hemoglobin, CVD, Short QT syndrome, Smartphone, Saliva, Degenerative disease, HPV, NASDAQ, Medical device, Prizma

IRVINE, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) (the “Company” or “G Medical Innovations”) today announced that its wholly owned subsidiary, G. Medical Health and Wellness, Inc., has developed seven different at-home tests that are expected to be available to consumers during Q3-2022 through popular big-box retail sites, pharmacies and Online. The tests developed for health issues ranging from food sensitivity, Indoor/Outdoor allergies, HPV, thyroid functioning, testosterone levels, and the hemoglobin A1C test, with results going directly to the user within days.

Key Points: 
  • The tests developed for health issues ranging from food sensitivity, Indoor/Outdoor allergies, HPV, thyroid functioning, testosterone levels, and the hemoglobin A1C test, with results going directly to the user within days.
  • This will allow them to quickly begin making any necessary health changes or follow up health care visits, said Dr. Yacov Geva, CEO of G Medical Innovations.
  • As Telehealth and Telemedicine industry pioneers, the management of G Medical Innovations has been offering patient home care monitoring and service for over 30 years.
  • G Medical Innovations Holdings Ltd. is a healthcare company engaged in the development of next-generation mHealth and telemedicine solutions and monitoring service platforms.

G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) Announces Receipt of Nasdaq Minimum Bid Price Notification

Retrieved on: 
Friday, June 17, 2022
Antibody, Solution, Laboratory, Security (finance), Vital signs, COVID-19, Risk, Cardiovascular disease, Degenerative disease, Notice, Compliance, Company, U.S. Securities and Exchange Commission, Smartphone, Private Securities Litigation Reform Act, CVD, Severe acute respiratory syndrome coronavirus 2, Intention, Calendar, MHealth, SEC, COVID-19 testing, Telehealth, Patient, ECG, GLOBE, Diabetes, Audit, Rope, Pharmaceutical industry, Nasdaq, Prizma

Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a period of 180 calendar days to regain compliance with the minimum bid price requirement.

Key Points: 
  • Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a period of 180 calendar days to regain compliance with the minimum bid price requirement.
  • According to the Notice, the Company has untilDecember 13, 2022 to regain compliance with the minimum bid price requirement.
  • About G Medical Innovations Holdings Ltd.
    G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms.
  • G Medical Innovations Holdings Ltd.

G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) Announces Share Repurchase Program

Retrieved on: 
Friday, May 20, 2022
Diabetes, Smartphone, MHealth, ERT (company), Vital signs, ECG, Company, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Share repurchase, Patient, NASDAQ, Solution, Degenerative disease, Risk, CVD, Short QT syndrome, Telehealth, Compliance, SEC, Cardiovascular disease, Annual report, GLOBE, Security (finance), Medical device, Prizma

Irvine, California, May 20, 2022 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd.(NASDAQ: GMVD) (theCompany) today announced that its board of directors has authorized a share repurchase program to acquire up to $1 million of the Company's ordinary shares (the Repurchase Plan).

Key Points: 
  • Irvine, California, May 20, 2022 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd.(NASDAQ: GMVD) (theCompany) today announced that its board of directors has authorized a share repurchase program to acquire up to $1 million of the Company's ordinary shares (the Repurchase Plan).
  • The Company may repurchase all or a portion of the authorized repurchase amount.
  • The Repurchase Plan does not obligate the Company to repurchase any specific number of the ordinary shares and may be suspended or terminated at any time at managements discretion.
  • G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms.

DGAP-News: G Medical Innovations (NASDAQ: GMVD) Provides Update Regarding its Forecast for Q1 2022 Revenues

Retrieved on: 
Thursday, May 19, 2022
Diabetes, Smartphone, MHealth, ERT (company), Vital signs, ECG, Company, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Patient, NASDAQ, Solution, Degenerative disease, Government, Risk, CVD, COVID-19, COVID-19 testing, Short QT syndrome, Telehealth, Congress, SEC, LLC, Security (finance), CA, Cardiovascular disease, Annual report, Pharmaceutical industry, Prizma

Irvine, CA May 18, 2022 G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) (the Company), today announced that it will not meet its forecast of $30 million in revenues for the first quarter of 2022.

Key Points: 
  • Irvine, CA May 18, 2022 G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) (the Company), today announced that it will not meet its forecast of $30 million in revenues for the first quarter of 2022.
  • The Company plans to announce the final revenues numbers for the first quarter of 2022 as part of its financial results release for the first six months of 2022.
  • G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms.
  • References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release.